Everything below concerns dihexa. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-05-08. Where a claim depends on a specific study, the study is described rather than over-claimed.
The compound has been examined in animal models for effects on learning, memory, and synaptic connectivity. Some reports describe increased dendritic spine density and improved performance on certain behavioral tasks after administration in rodents. These findings are often cited in discussions of nootropic research peptides, but replication across independent laboratories remains limited. The absence of published phase 1 or phase 2 clinical trial data makes it difficult to assess safety, effective routes, or long-term outcomes in humans. Consequently, claims about cognitive benefits in people remain speculative.
Dihexa is not approved as a medicine in major regulatory jurisdictions. It is commonly sold as a research chemical for laboratory use, though such products may not be standardized or independently verified. Scientific literature on dihexa includes in vitro assays, rodent studies, and reviews that discuss its proposed mechanism. The distinction between peer-reviewed findings and commercial promotion is important when evaluating available information. Open questions include its precise binding interactions, pharmacokinetics, and whether animal results translate to human biology.
Dihexa is commonly handled as a lyophilized powder in laboratory settings. Storage at -20 °C in a desiccated, light-protected container is typical for peptides. Repeated freeze-thaw cycles can degrade the material, so aliquoting is often recommended. Aqueous solutions may be less stable than organic stocks and should be prepared fresh when possible. Personnel should follow institutional safety procedures and avoid uncontrolled exposure. Because human effects are not well characterized, handling precautions are prudent.
The proposed mechanism of dihexa centers on activation of the hepatocyte growth factor receptor, also called c-Met. Some studies suggest it acts as a mimetic of hepatocyte growth factor, promoting signaling pathways involved in synapse formation. Other work has explored interactions with angiotensin IV pathways, but the exact binding targets remain uncertain. Laboratory findings come mainly from cell cultures and animal models. Whether these mechanisms operate similarly in humans is an open question. Researchers have not established a single, universally accepted mechanism of action.
Identity and purity of dihexa samples are typically assessed with high-performance liquid chromatography and mass spectrometry. These methods can confirm molecular mass and estimate the presence of impurities. However, a certificate of analysis from a supplier is not a guarantee of independent testing. Researchers often require in-house verification before using a peptide in experiments. For solid samples, appearance, solubility, and chromatographic profile provide additional checks. Nuclear magnetic resonance may be used for structural confirmation when available.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide | Derived from angiotensin IV and modified for stability. |
| Proposed mechanism | c-Met/HGF pathway activation | Described as an HGF mimetic in experimental systems. |
| Common synonyms | Dihexa; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Name usage varies by supplier and publication. |
| Regulatory status | Not approved as a drug | Sold as a research chemical in some markets. |
| Human trial data | Limited or absent | Most evidence comes from preclinical studies. |
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
== Social factors == The general public's impression of semaglutide is that it is an "easy way out" to lose weight by taking a prescription instead of altering one's lifestyle. This narrative is complicated by anthropologist Sissel Due Jensen and associates' investigation of semaglutide use in three Danish general practices. According to their findings, treatment involves more than just taking medication and losing weight. Rather, in reaction to adverse effects, financial limitations, and individual circumstances, patients and clinicians constantly "tinker" with dosage, timing, and administration. Even if treatment interferes with their daily lives, patients also put considerable effort into obtaining and maintaining access to the medication.
== Development and social impact == John Rolfe of Virginia used this species of tobacco to break the Spanish monopoly on tobacco in 1612. He did so by obtaining Nicotiana tabacum - the coveted plant he had designs to replace Nicotiana rustica with. Up until 1612, Nicotiana rustica was Virginia's only tobacco crop, and was found by Englishmen to be too bitter for enjoyment. Rolfe, by successfully planting, maintaining, and curing Nicotiana tabacum until sale (by removing all superfluous leaves and applying as little water as possible during curing), made Virginia a potential competitor with Spain's colonies. This transitioned the colony to a cash-crop focused one, monocropping tobacco by 1613, the year the first shipment (of 4 barrels) arrived in London. By 1617, the quality of Virginia tobacco had made it the gold standard in European markets, which have become insatiable- 20,000lbs of tobacco was exported there that year. These exports grew exponentially, doubling to 40,000lbs the following year (the year the first enslaved Africans arrive in America), and reaching 60,000lbs by 1620. The money obtained from tobacco exports was used, in turn, to fund the purchasing of more European indentured servants and especially enslaved Africans to fulfill the rising labor demand. In the 17th century, 75% of all colonists in Virginia had come as servants, indentured (with a term of 4 to 7 years of service) or Africans in perpetuity (for life), the latter being preferred as they were cheaper sources of labor:
== Interactions == There are a few types of medications that interact with valsartan. Combined use with nonsteroidal anti-inflammatory drugs (NSAID) such as naproxen or ibuprofen can result in kidney injury in people who are elderly, dehydrated, or have reduced kidney function. One study conducted Lapi F., et al. found that there was no increased risk of kidney injury when only using either a diuretic or angiotensin receptor blocker with an NSAID but did find an increased risk when all three medications were used together. Valsartan usage with angiotensin receptor blocker, ACE inhibitors, or aliskiren results in additive side effects.
== Further reading == Kleerebezem M, Boekhorst J, van Kranenburg R, et al. (February 2003). "Complete genome sequence of Lactobacillus plantarum WCFS1". Proceedings of the National Academy of Sciences of the United States of America. 100 (4): 1990–1995. Bibcode:2003PNAS..100.1990K. doi:10.1073/pnas.0337704100. JSTOR 3138472. PMC 149946. PMID 12566566.
A revolution in nuclear strategic thought occurred with the introduction of the intercontinental ballistic missile (ICBM), which the Soviet Union first successfully tested in August 1957. In order to deliver a warhead to a target, a missile was much faster and more cost-effective than a bomber, and enjoyed a higher survivability due to the enormous difficulty of interception of the ICBMs (due to their high altitude and extreme speed). The Soviet Union could now afford to achieve nuclear parity with the United States in raw numbers, although for a time, they appeared to have chosen not to. Photos of Soviet missile sites set off a wave of panic in the U.S. military, something the launch of Sputnik would do for the American public a few months later. Politicians, notably then-U.S. Senator John F. Kennedy suggested that a "missile gap" existed between the Soviet Union and the United States. The US military gave missile development programs the highest national priority, and several spy aircraft and reconnaissance satellites were designed and deployed to observe Soviet progress. Early ICBMs and bombers were relatively inaccurate, which led to the concept of countervalue strikes — attacks directly on the enemy population, which would theoretically lead to a collapse of the enemy's will to fight. During the Cold War, the Soviet Union invested in extensive protected civilian infrastructure, such as large "nuclear-proof" bunkers and non-perishable food stores.
Sources: en.wikipedia.org
ASR-2001 (2CB-5PrO) is a propoxy TWEETIO and another notable analogue of 2C-B which is under development for treatment of psychiatric disorders. FLY derivatives of 2C-B like 2C-B-FLY, 2C-B-DRAGONFLY, and 2C-B-BUTTERFLY are analogues in which the methoxy groups of 2C-B on the phenyl ring have been cyclized into furan or other rings to form benzodifuran and other tricyclic compounds. 2-OH-2C-B is the 2-O-desmethylated analogue of 2C-B and shows similar potency as a serotonin 5-HT2A receptor agonist in vitro. Cyclized phenethylamine derivatives of 2C-B in which the side chain has been cyclized in some way include DOB-CR (2C-B-CR), 2CB-Ind, 2C-B-5-hemiFLY-α6 (BNAP), 2CB7 (2C-B-5-hemiFLY-β7), TCB-2 (2CBCB), 2C-B-PYR, 2C-B-3PIP, 2C-B-3PIP-NBOMe, 2C-B-3PIP-POMe, 2CBecca, 2CJP, 2CLisaB, ZC-B, 2C-B-aminorex (2C-B-AR), and 2C-B-morpholine (2C-B-MOR), among others. Other related cyclized compounds, while not technically phenethylamines or 2C-B derivatives, include 2C-B-BZP and 2C-B-PP. A notable positional isomer of 2C-B is the scaline and mescaline analogue 4-bromomescaline (4-Br-3,5-DMPEA). Deuterated isotopologues of 2C-B such as 2CB-2OCD3 (2-trideuteromethoxy-2C-B), 2CB-5OCD3 (5-trideuteromethoxy-2C-B), and hexadeutero-2C-B (2,5-di(trideuteromethoxy)-2C-B) among others have been described.
P-glycoprotein (3.A.1.201.1) is a well-studied protein associated with multi-drug resistance. It belongs to the human ABCB (MDR/TAP) family and is also known as ABCB1 or MDR1 Pgp. MDR1 consists of a functional monomer with two transmembrane domains (TMD) and two nucleotide-binding domains (NBD). This protein can transport mainly cationic or electrically neutral substrates as well as a broad spectrum of amphiphilic substrates. The structure of the full-size ABCB1 monomer was obtained in the presence and absence of nucleotide using electron cryo crystallography. Without the nucleotide, the TMDs are approximately parallel and form a barrel surrounding a central pore, with the opening facing towards the extracellular side of the membrane and closed at the intracellular face. In the presence of the nonhydrolyzable ATP analog, AMP-PNP, the TMDs have a substantial reorganization with three clearly segregated domains. A central pore, which is enclosed between the TMDs, is slightly open towards the intracellular face with a gap between two domains allowing access of substrate from the lipid phase. Substantial repacking and possible rotation of the TM helices upon nucleotide binding suggests a helix rotation model for the transport mechanism.
== History == In 1939, Martin Kamen and Samuel Ruben of the Radiation Laboratory at Berkeley began experiments to determine if any of the elements common in organic matter had isotopes with half-lives long enough to be of value in biomedical research. They synthesized 14C using the laboratory's cyclotron accelerator and soon discovered that the atom's half-life was far longer than had been previously thought. This was followed by a prediction by Serge A. Korff, then employed at the Franklin Institute in Philadelphia, that the interaction of thermal neutrons with 14N in the upper atmosphere would create 14C. It had previously been thought that 14C would be more likely to be created by deuterons interacting with 13C. At some time during World War II, Willard Libby, who was then at Berkeley, learned of Korff's research and conceived the idea that it might be possible to use radiocarbon for dating.
== Reception == The game was generally well received. Charlie Hill of Polygon called it "absolutely brilliant". Aaron Zimmerman stated in a review for Ars Technica that the artwork is "top-notch" and the card stock is of good quality.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide derived from angiotensin IV and studied for effects on synaptic plasticity. It is often described as a hepatocyte growth factor mimetic. It is not an approved medication.
It is based on angiotensin IV, a naturally occurring peptide fragment, but dihexa itself is chemically modified and synthetic. The modifications aim to improve stability and activity compared with the parent fragment.
Laboratory studies have used cell-based assays and rodent models. These examine receptor signaling, dendritic spine changes, and behavioral tasks. Published human clinical trial data are lacking.
Liquid chromatography–mass spectrometry is commonly used. It provides molecular mass and purity information. Other methods may include HPLC with ultraviolet detection.